Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.

Pharmacogenomics

MRC Centre for Neuropsychiatric Genetics & Genomics, Division of Psychological Medicine & Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, CF24 4HQ, UK.

Published: March 2019

AI Article Synopsis

Article Abstract

Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. In this article, we provide an overview of the current understanding of the genetics of clozapine-associated agranulocytosis and neutropenia. We now know that the genetic etiology of clozapine-associated neutropenia is complex and is likely to involve variants from several genes including HLA-DQB1, HLA-B and SLCO1B3/SLCO1B7. We describe recent findings relating to the Duffy-null genotype and its association with benign neutropenia in individuals with African ancestry. Further advances will come from sequencing studies, large, cross-population studies and in understanding the molecular mechanisms underlying these associations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563116PMC
http://dx.doi.org/10.2217/pgs-2018-0188DOI Listing

Publication Analysis

Top Keywords

genetics clozapine-associated
8
clozapine-associated neutropenia
8
agranulocytosis neutropenia
8
neutropenia
5
neutropenia advances
4
advances challenges
4
challenges future
4
future perspective
4
perspective clozapine
4
clozapine effective
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!